Cohort compassionate-use program and early access program with cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: analysis by age group

Date issued
2015Journal title
BJU INTERNATIONAL
Type of content
Publicación de congreso
